Published in Theranostics on January 01, 2016
Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment. Bioconjug Chem (2015) 0.78
Novel molecular "add-on" based on Evans Blue confers superior pharmacokinetics and transforms drugs to theranostic agents. J Nucl Med (2016) 0.75
Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing. Proc Natl Acad Sci U S A (2017) 0.75
CLINICAL STUDIES OF THE BLOOD VOLUME. I. CLINICAL APPLICATION OF A METHOD EMPLOYING THE AZO DYE "EVANS BLUE" AND THE SPECTROPHOTOMETER. J Clin Invest (1937) 84.46
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care (2005) 7.07
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 6.64
Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta (1971) 6.06
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care (2005) 5.77
Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes (1999) 5.10
PEGylation, successful approach to drug delivery. Drug Discov Today (2005) 4.56
Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release (2008) 3.62
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev (2003) 2.78
Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev (1997) 2.74
Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother (2006) 2.59
Management of type 2 diabetes: new and future developments in treatment. Lancet (2011) 2.57
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab (2001) 2.24
Peptide and protein PEGylation: a review of problems and solutions. Biomaterials (2001) 2.00
The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res (2004) 1.96
PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev (2002) 1.84
Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem (2002) 1.76
A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A (1994) 1.52
Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT. Eur J Nucl Med Mol Imaging (2014) 1.48
Therapeutic strategies based on glucagon-like peptide 1. Diabetes (2004) 1.39
AMINO ACID COMPOSITION OF HUMAN AND BOVINE SERUM MERCAPTALBUMINS. J Biol Chem (1964) 1.31
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol (2013) 1.31
Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res (2002) 1.31
Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Devel (2008) 1.27
Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab (2008) 1.15
PET of insulinoma using ¹⁸F-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm (2011) 1.07
PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur J Cancer (2002) 1.06
Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J Pharm Sci (1997) 1.03
Exenatide. Nat Rev Drug Discov (2005) 1.02
In Vivo Labeling of Serum Albumin for PET. J Nucl Med (2014) 0.99
Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol (2012) 0.95
Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J Pharmacol Exp Ther (1996) 0.94
Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Hum Exp Toxicol (2007) 0.94
Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I. Int J Rad Appl Instrum B (1990) 0.92
Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood (1997) 0.92
In vivo albumin labeling and lymphatic imaging. Proc Natl Acad Sci U S A (2014) 0.89
Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics. Bioconjug Chem (2011) 0.87
Clinical Translation of an Albumin-Binding PET Radiotracer 68Ga-NEB. J Nucl Med (2015) 0.85
Human serum albumin conjugated biomolecules for cancer molecular imaging. Curr Pharm Des (2012) 0.84
Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes (1997) 0.82
Albumin-insulin conjugate releasing insulin slowly under physiological conditions: a new concept for long-acting insulin. Bioconjug Chem (2005) 0.82
Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia. Int J Pharm (2011) 0.81
Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers. J Pharm Sci (2009) 0.79
Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules. Biochem Pharmacol (1993) 0.78
Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3. Theranostics (2016) 1.02